Rocket Pharmaceuticals, Inc. financial data

Symbol
RCKT, RCKTW on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Fifth Avenue, Suite 7530, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
INOTEK PHARMACEUTICALS CORP (to 12/22/2017)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 791 % -25.2%
Debt-to-equity 15.6 % +26%
Return On Equity -62.6 % -17.3%
Return On Assets -54.2 % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91.2M shares +1.11%
Common Stock, Shares, Outstanding 91.1M shares +1.08%
Entity Public Float 1.2B USD +86.2%
Common Stock, Value, Issued 911K USD +1.11%
Weighted Average Number of Shares Outstanding, Basic 94.2M shares +13.9%
Weighted Average Number of Shares Outstanding, Diluted 94.2M shares +13.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 176M USD -9.76%
General and Administrative Expense 98.2M USD +38.6%
Operating Income (Loss) -274M USD -3.14%
Net Income (Loss) Attributable to Parent -258M USD -2.15%
Earnings Per Share, Basic -2.73 USD/shares +14.4%
Earnings Per Share, Diluted -2.73 USD/shares +14.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 65.6M USD -70.9%
Cash, Cash Equivalents, and Short-term Investments 236M USD -46.1%
Assets, Current 242M USD -45.9%
Property, Plant and Equipment, Net 38.5M USD +5.42%
Operating Lease, Right-of-Use Asset 4.35M USD +6.36%
Intangible Assets, Net (Excluding Goodwill) 25.2M USD 0%
Goodwill 39.2M USD 0%
Assets 394M USD -34.3%
Employee-related Liabilities, Current 10.3M USD +23.4%
Liabilities, Current 40M USD +19.4%
Operating Lease, Liability, Noncurrent 3.41M USD +14.1%
Other Liabilities, Noncurrent 1.14M USD -38.9%
Liabilities 63.9M USD +10.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 213K USD
Retained Earnings (Accumulated Deficit) -1.16B USD -28.7%
Stockholders' Equity Attributable to Parent 330M USD -39.1%
Liabilities and Equity 394M USD -34.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -56.9M USD +1.22%
Net Cash Provided by (Used in) Financing Activities 1.18M USD -93.5%
Net Cash Provided by (Used in) Investing Activities 35M USD
Common Stock, Shares Authorized 180M shares +50%
Common Stock, Shares, Issued 91.1M shares +1.08%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 67M USD -70.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 108M USD +18.9%
Operating Lease, Liability 4.42M USD +8.58%
Payments to Acquire Property, Plant, and Equipment 2.04M USD -32.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -257M USD -1.9%
Lessee, Operating Lease, Liability, to be Paid 5.96M USD +3.63%
Property, Plant and Equipment, Gross 57.9M USD +17.8%
Operating Lease, Liability, Current 1.01M USD -6.86%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.01M USD +86.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1M USD +10.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.55M USD -8.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 759K USD +39.3%
Deferred Tax Assets, Operating Loss Carryforwards 45.3M USD +34.4%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 522K USD +3.16%
Operating Lease, Payments 333K USD +27.6%
Additional Paid in Capital 1.49B USD +3.2%
Depreciation, Depletion and Amortization 6.8M USD +58.3%
Share-based Payment Arrangement, Expense 42.8M USD +9.17%
Interest Expense 1.88M USD +0.53%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%